# Early hGH Treatment of SGA Infants to Prevent Irreversible Neurologic and Psychological Damage and Sequelae

> **NCT02326610** · PHASE2 · UNKNOWN · sponsor: **Tel-Aviv Sourasky Medical Center** · enrollment: 20 (estimated)

## Conditions studied

- Infant, Small for Gestational Age
- Growth Hormone Treatment
- Infant, Premature, Diseases

## Interventions

- **DRUG:** Human growth hormone,ZOMACTON® (somatropin)

## Key facts

- **NCT ID:** NCT02326610
- **Lead sponsor:** Tel-Aviv Sourasky Medical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-12
- **Primary completion:** 2017-12
- **Final completion:** 2018-12
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2014-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02326610

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02326610, "Early hGH Treatment of SGA Infants to Prevent Irreversible Neurologic and Psychological Damage and Sequelae". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02326610. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*